Table 3.
Cost of therapy
| Phase of treatment | ≤15 years | >15–<60 years |
|---|---|---|
| Induction | n = 19a | n = 49b |
| Mean |
 523 543 ($8500) |
 742 387 ($12 300) |
| Standard deviation |
 176 800 ($2900) |
 386 991 ($ 6 344) |
| Consolidation | n = 14@ | n = 25# |
| Mean |
 1 231 965 ($20 200) |
 318 128 ($5200) |
| Standard deviation |
 695 546 ($11 400) |
 135 040 ($2200) |
| Transplant | n = 4^ | n = 14^ |
| Mean |
 1 462 586 ($23 574) |
 1 983 051 ($32 500) |
| Standard deviation |
 588 099 ($9600) |
 1 031 835 ($16 900) |
a
Excludes induction deaths.
b
Excludes induction deaths and those that received hypomethylating agents.
: Indian Rupee :United Statesdollar (calculationbasedonone US = 61
). @ Includes 4 cycles of consolidation chemotherapy as part of AML‐BFM 98 protocol. # Only for those that received high dose cytosine arabinoside (HiDAC) consolidation (25 patients and 56 consolidations); the calculated amount is cost per cycle of HiDAC consolidation. ^ Allogeneic stem cell transplantation only. Calculated cost includes all costs incurred over multiple admissions over the period of this study.